Ursula A. Matulonis, MD, on Key Takeaways from the KEYNOTE-100 Trial in Ovarian Cancer

June 10, 2020

The Dana-Farber Cancer Institute expert discussed pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

Final results from the KEYNOTE-100 trial of pembrolizumab (Keytruda) in patients with advanced recurrent ovarian cancer suggested that the agent alone was associated with modest antitumor activity.

Additionally, the study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, did not identify any new safety signals.

In an interview with CancerNetwork®, Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, discussed the implications of this study and the next steps for the final analysis.

Transcription:

Yeah, so I think the key takeaway points are that pembrolizumab, like other single agent immune checkpoint inhibitors, in ovarian cancer has moderate only moderate activity as a single agent. This has been observed with other single agent checkpoint inhibitors as well. The activity of pembrolizumab appears higher in ovarian cancers that have higher combined positive scores, so have higher levels of PD-L1 expression. And also, there was a higher trend towards increased response rate for patients with clear cell histology, and that's also been observed in other single agent checkpoint blockade studies in ovarian cancer. The median duration of response if a patient did have a response was around 10.2 months, which is very good. No new safety signals were identified. And further biomarker analysis is ongoing to try to really maybe potentially select out patients who may benefit more from single agent pembrolizumab.